NGM Biopharmaceuticals, Inc.
NASDAQ:NGM
1.54 (USD) • At close April 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | NGM Biopharmaceuticals, Inc. |
Symbool | NGM |
Munteenheid | USD |
Prijs | 1.54 |
Beurswaarde | 128,532,096 |
Dividendpercentage | 0% |
52-weken bereik | 0.6 - 4.69 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. David J. Woodhouse Ph.D. |
Website | https://www.ngmbio.com |
An error occurred while fetching data.
Over NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)